Contact Us / Sitemap / Directions / Patients and Visitors / Career Opportunities / Medical Staff
1-866-WINTHROP
pay your hospital bill pay your doctor's bill financial assistance policy
Winthrop University Hospital

Stage IB-IIIA Non-Small Cell Lung Cancer

Summary

This phase III study is for patients who have non small cell lung cancer. The pupose of this study is to find out if adding the new drug Bevacizumab (avastin) to chemotherapy improves the chance of a cure for patients who have had surgery for the removal of their lung cancer.

Description

The study will evaluate the effects (good and bad) of a standard combination of chemotherapy drugs when given with and without the new drug, bevacizumab. The chemotherapy regimen drugs are: Cisplatin and Vinorelbine, Cisplatin and Docetaxel, Cisplatin and Gemcitabine.

Inclusion/exclusion

Patients must undergo study specific types of lung surgery to remove the tumor with study specific staging. Patients must be recovering well from their lung surgery at least 6 weeks and up to 12 weeks before starting their study medication.

Principal Investigator

Jeffrey Schneider MD

Department

Oncology/Hematology

Email

jschneider@winthrop.org

Other Contact

mstanganelli@winthrop.org
Contact Us / Sitemap / Directions / Career Opportunities / Financial Assistance / Policies
1-866-WINTHROP
subscribe
Winthrop-University Hospital
259 First Street | Mineola NY 11501 | 516-663-0333


This site provides information as a resource. It is not a substitute for professional medical advice.
Always consult a physician or healthcare provider for treatment and guidance toward good health.
Copyright © 2014 Winthrop-University Hospital. All rights reserved.
Web site by: Long Island Web Design
page-bottom